| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9959764 | Journal of the American College of Cardiology | 2005 | 8 Pages |
Abstract
The LPL C/G polymorphism (Ser447Ter), resulting in a truncation of the two C-terminal amino acids of the mature LPL protein, appears to be an important protective factor for TVR in humans. The role of LPL in this process was further established in a mouse model, where LPL expression was very strongly up-regulated in the target arterial wall, suggesting a contribution of this lipolytic enzyme to restenosis. Possibly, LPL Ser447Ter genotyping may lead to better risk stratification and tailored therapy in the prevention of restenosis after PCI.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Pascalle S. MSc, Jamal S. MD, Melchior C. MD, Nuno M.M. MSc, Aeilko H. PhD, John J.P. MD, PhD, Jan Albert PhD, Moniek P.M. PhD, Saskia Z.H. MD, Abbey MD, Pieter A.F. MD, PhD, Robbert J. MD, PhD, René A. MD, PhD, Rune R. PhD, Paul H.A. PhD, Arnoud PhD,